Xu Haiying, general manager of Harbin Pharmaceutical Co., Ltd., resigned Post date May 16, 2022 — 17:30 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned from the company's director, member of the strategy and decision-making committee of the board of directors, and general manager Post date May 16, 2022 — 17:27 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned as director of the company, member of the strategy and decision-making committee of the board of directors, and general manager_Oriental Fortune Net Post date May 16, 2022 — 17:26 Post Lock Read More Xu Haiying, General Manager of Harbin Pharmaceutical Co., Ltd. (600664.SH), resigns Post date May 16, 2022 — 17:25 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline Post date May 13, 2022 — 11:03 Post Lock Read More Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned from the company's director, member of the strategy and decision-making committee of the board of directors, and general manager Post date May 16, 2022 — 17:27 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned as director of the company, member of the strategy and decision-making committee of the board of directors, and general manager_Oriental Fortune Net Post date May 16, 2022 — 17:26 Post Lock Read More Xu Haiying, General Manager of Harbin Pharmaceutical Co., Ltd. (600664.SH), resigns Post date May 16, 2022 — 17:25 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline Post date May 13, 2022 — 11:03 Post Lock Read More Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned as director of the company, member of the strategy and decision-making committee of the board of directors, and general manager_Oriental Fortune Net Post date May 16, 2022 — 17:26 Post Lock Read More Xu Haiying, General Manager of Harbin Pharmaceutical Co., Ltd. (600664.SH), resigns Post date May 16, 2022 — 17:25 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline Post date May 13, 2022 — 11:03 Post Lock Read More Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Xu Haiying, General Manager of Harbin Pharmaceutical Co., Ltd. (600664.SH), resigns Post date May 16, 2022 — 17:25 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline Post date May 13, 2022 — 11:03 Post Lock Read More Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline Post date May 13, 2022 — 11:03 Post Lock Read More Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com Post date May 13, 2022 — 08:55 Post Lock Read More Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years Post date May 13, 2022 — 08:50 Post Lock Read More [Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network Post date May 12, 2022 — 22:57 Post Lock Read More [Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network Post date May 11, 2022 — 18:55 Post Lock Read More Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shanghai and Shenzhen stock market trading tips (May 11) Post date May 11, 2022 — 09:40 Post Lock Read More Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network Post date April 28, 2022 — 17:44 Post Lock Read More Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 23:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 23:16 Post Lock Read More Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online Post date April 27, 2022 — 22:37 Post Lock Read More Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm Post date April 27, 2022 — 22:15 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network Post date April 27, 2022 — 21:23 Post Lock Read More Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs Post date April 27, 2022 — 21:21 Post Lock Read More Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year Post date April 24, 2022 — 22:44 Post Lock Read More 2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year. Post date April 18, 2022 — 13:42 Post Lock Read More Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted. Post date April 18, 2022 — 13:25 Post Lock Read More
Caishen.CoCaishen.Co